e-SPACE Cardio-Renal-Metabolic 2022: On-demand
Published: 11 April 2022
-
Views:
9704
-
Likes:
7
-
Views:
9704
-
Likes:
7
-
Part 26 | Session 1 Meet the Expert: SGLT2, the statin of the 21st century
-
Part 27 | Session 1 Introduction
-
Part 27 | Session 2 DAPA CKD: Key lessons from subgroup analyses
-
Part 27 | Session 3 FIDELIO/FIGARO DKD
-
Part 27 | Session 4 FIDELITY - Main lessons including subgroup analyses
-
Part 27 | Session 5 Chlortalidone in CKD stage 4: A new look at an old drug
-
Part 27 | Session 6 Panel discussion
-
Part 28 | Session 1 Introduction
-
Part 28 | Session 2 Screening and diagnosis best practices
-
Part 28 | Session 3 Primary care perspective and challenges
-
Part 28 | Session 4 Reducing CV risks and new treatment options: case discussion
-
Part 28 | Session 5 Panel discussion
-
Part 29 | Session 1 Introduction
-
Part 29 | Session 2 Digital technologies in CV disease
-
Part 29 | Session 3 Remote monitoring of HF
-
Part 29 | Session 4 Telemedicine in CKD from a cardiologist's perspective
-
Part 29 | Session 5 Panel discussion
-
Part 30 | Session 1 Introduction
-
Part 30 | Session 2 Ascend D and ASCEND ND
-
Part 30 | Session 3 The moving field of drug nephrotoxicity
-
Part 30 | Session 4 The role of new potassium binding agents in cardio-renal medicine
-
Part 30 | Session 5 Panel discussion
-
Part 31 | Session 1 Meet the Expert: Management of worsening HF
-
Part 32 | Session 1 Introduction
-
Part 32 | Session 2 Cardio-centric approach
-
Part 32 | Session 3 Gluco-centric approach
-
Part 32 | Session 4 Combination therapy as starting option
-
Part 32 | Session 5 Panel discussion
-
Part 1 | Session 1 Meet the Expert: IgA nephropathy: current optimal management Sydney Tang
-
Part 2 | Session 1 Welcome and introduction
-
Part 2 | Session 2 1.1: BP in CKD Guidelines
-
Part 2 | Session 3 1.2: Diabetes and CKD GL
-
Part 2 | Session 4 1.3: General management of the nephrotic syndrome
-
Part 2 | Session 5 Panel Discussion
-
Part 3 | Session 1 Welcome and Introduction Ewa Jankowska
-
Part 3 | Session 2 Management of iron deficiency in heart failure: new evidence, new guidelines
-
Part 3 | Session 3 Iron deficiency in chronic kidney disease: why iron matters beyond anaemia
-
Part 3 | Session 4 Interactive panel discussion
-
Part 4 | Session 1 Introduction Vijay Chopra, Marco Metra
-
Part 4 | Session 2 2.1: The new ESC HF guidelines
-
Part 4 | Session 3 2.2: Personalised management
-
Part 4 | Session 4 2.3: Preventive cardiology
-
Part 4 | Session 5 Panel Discussion
-
Part 6 | Session 1 Introduction Andrew JS Coats, Alice Cheng
-
Part 6 | Session 2 3.1: Focus on diabetology Andrew JS Coats, Alice Cheng
-
Part 6 | Session 3 3.2: Focus on cardiology Andrew JS Coats, Alice Cheng
-
Part 6 | Session 4 3.3: Focus on nephrology Andrew JS Coats, Alice Cheng
-
Part 6 | Session 5 Panel Discussion Andrew JS Coats, Alice Cheng
-
Part 7 | Session 1 Introduction Roland E Schmieder
-
Part 7 | Session 2 The meaning of Hemoglobin A1C for the nephrologist Roland E Schmieder
-
Part 7 | Session 3 The meaning of Hemoglobin A1C for the cardiologist Roland E Schmieder
-
Part 7 | Session 4 Panel discussion Roland E Schmieder
-
Part 8 | Session 1 Introduction
-
Part 8 | Session 2 4.1: GLP-1RA and CVD in diabetes
-
Part 8 | Session 3 4.2: GLP-1 RA and kidney disease in diabetes
-
Part 8 | Session 4 4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA
-
Part 8 | Session 5 Panel discussion
-
Part 9 | Session 1 Welcome and introduction Andrew JS Coats
-
Part 9 | Session 2 Cardio-renal-metabolic disease in a nutshell Andrew JS Coats
-
Part 9 | Session 3 SGLT2 inhibitors in patients with type 2 diabetes and comorbidities Andrew JS Coats
-
Part 9 | Session 4 SGLT2 inhibitors in patients with heart failure and comorbidities Andrew JS Coats
-
Part 9 | Session 5 SGLT2 inhibitors in patients with chronic kidney disease and comorbidities Andrew JS Coats
-
Part 9 | Session 6 Panel discussion Andrew JS Coats
-
Part 10 | Session 1 Introduction
-
Part 10 | Session 2 5.1: Diagnosis, pathophysiology, epidemiology
-
Part 10 | Session 3 5.2: Diabetes
-
Part 10 | Session 4 5.3: In chronic kidney disease
-
Part 10 | Session 6 Panel discussion
-
Part 11 | Session 1 Introduction Mustafa Arici, Pardeep Jhund
-
Part 11 | Session 2 Mechanism of disease interplay between CVD and CKD Mustafa Arici, Pardeep Jhund
-
Part 11 | Session 3 The use of SGLT2is in patients with CKD and CVD with and without diabetes Mustafa Arici, Pardeep Jhund
-
Part 11 | Session 4 Panel discussion Mustafa Arici, Pardeep Jhund
-
Part 12 | Session 1 Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM Stefan Anker
-
Part 13 | Session 1 Introduction Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
Part 13 | Session 2 6.1: EMPEROR-Preserved Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
Part 13 | Session 3 6.2: Preserved HF Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
Part 13 | Session 4 6.3: Dronedarone in AF management: A 2022 update Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
Part 13 | Session 5 6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man) Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
Part 13 | Session 6 Panel discussion Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
Part 14 | Session 1 Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group Silvio Inzucchi, Milton Packer
-
Part 15 | Session 1 Introduction Javed Butler
-
Part 15 | Session 2 The case for early identification, risk stratification and treatment of CKD Javed Butler
-
Part 15 | Session 3 Protecting the kidney and the heart: the cardiologist's perspective Javed Butler
-
Part 15 | Session 4 Identifying high-risk patients: the primary care physician's perspective Javed Butler
-
Part 15 | Session 5 Panel discussion Javed Butler
-
Part 16 | Session 1 Welcome and introduction Stefan Anker, Stephan Von Haehling
-
Part 16 | Session 2 8.1: Cachexia in CV disease Stefan Anker, Stephan Von Haehling
-
Part 16 | Session 3 8.2: Cachexia in CKD Stefan Anker, Stephan Von Haehling
-
Part 16 | Session 4 8.3: Muscle wasting in stroke Stefan Anker, Stephan Von Haehling
-
Part 16 | Session 5 Panel discussion Stefan Anker, Stephan Von Haehling
-
Part 17 | Session 1 Meet the Expert: HIF PHI: What do we know and don't know in 2022 David Wheeler
-
Part 18 | Session 1 Introduction Giuseppe Rosano
-
Part 18 | Session 2 9.1: Diabetes and CVD today Giuseppe Rosano
-
Part 18 | Session 3 9.2: Diabetes and kidney today Giuseppe Rosano
-
Part 18 | Session 4 9.3: The cross-talk between kidney and heart Giuseppe Rosano
-
Part 18 | Session 5 9.4: Therapeutic solution Giuseppe Rosano
-
Part 18 | Session 6 Panel discussion Giuseppe Rosano
-
Part 19 | Session 1 SGLT2 inhibition in the comorbid CKD patient Muthiah Vaduganathan
-
Part 19 | Session 2 Panel discussion Muthiah Vaduganathan
-
Part 20 | Session 1 Introduction
-
Part 20 | Session 2 10.1: Screening of kidney disease
-
Part 20 | Session 3 10.2: Screening of heart failure
-
Part 20 | Session 4 10.3: Horizons opened by the screening
-
Part 20 | Session 5 Panel discussion
-
Part 21 | Session 1 Welcome and introduction Shelley Zieroth, Giuseppe Rosano
-
Part 21 | Session 2 New developments in SGLT2 inhibitor use in HFrEF and HFpEF Shelley Zieroth, Giuseppe Rosano
-
Part 21 | Session 3 Implementing guidelines in clinical practice Shelley Zieroth, Giuseppe Rosano
-
Part 21 | Session 4 Panel discussion Shelley Zieroth, Giuseppe Rosano
-
Part 22 | Session 1 Introduction Piotr Ponikowski, Muthiah Vaduganathan
-
Part 22 | Session 2 In ambulatory HFrEF and HFpEF Piotr Ponikowski, Muthiah Vaduganathan
-
Part 22 | Session 3 When to start after acute decompensation Piotr Ponikowski, Muthiah Vaduganathan
-
Part 22 | Session 4 Improving QoL and symptoms Piotr Ponikowski, Muthiah Vaduganathan
-
Part 22 | Session 5 The case of acute MI Piotr Ponikowski, Muthiah Vaduganathan
-
Part 22 | Session 6 Panel discussion Piotr Ponikowski, Muthiah Vaduganathan
-
Part 23 | Session 1 Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist Kevin Damman
-
Part 24 | Session 1 Introduction Stefan Anker, Linda Mellbin
-
Part 24 | Session 2 Practical issues of managing weight loss in CRM disease: the therapeutic options Stefan Anker, Linda Mellbin
-
Part 24 | Session 3 Managing weight loss in CRM disease: the nephrologist's perspective Stefan Anker, Linda Mellbin
-
Part 24 | Session 4 Managing weight loss in CRM disease: the diabetologist's perspective Stefan Anker, Linda Mellbin
-
Part 24 | Session 5 Managing weight loss in CRM disease: the cardiologists' perspective Stefan Anker, Linda Mellbin
-
Part 24 | Session 6 Panel discussion Stefan Anker, Linda Mellbin
-
Part 25 | Session 1 Welcome and introduction Ileana L Piña, Bertram Pitt
Overview
e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.
The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.
This on-demand version of the event comprises:
- Presentations and discussions with leading experts
- Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
- Insight to SLGT2i, GLP-1RA and other emerging therapies
- 'Meet the Expert' sessions

More from this programme
Part 1
Meet the Expert: IgA nephropathy: current optimal management
Part 2
Session 1: The new KDIGO guidelines
Part 3
Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk
Part 4
Session 2: Recent CV guidelines and treatment algorithms
Part 5
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes
Part 6
Session 3: Management of SGLT2 a practical approach
Part 7
Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist
Part 8
Session 4: GLP-1RA and cardio-metabolic disease in diabetes
Part 9
Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey
Part 10
Session 5: HFpEF: tackling a multidisciplinary problem
Part 11
Meet the Experts: CKD progression in CVD screening and follow-up
Part 12
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM
Part 13
Session 6: New trial update in cardiology
Part 14
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group
Part 15
Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney
Part 16
Session 8: Sarcopenia, frailty malnutrition and cachexia
Part 17
Meet the Expert: HIF PHI: What do we know and don't know in 2022
Part 18
Session 9: The cardio-kidney interaction: relevance to diabetes
Part 19
Industry Session: SGLT2 inhibition in the comorbid CKD patient
Part 20
Session 10: Why and how to screen for heart failure and kidney disease in diabetes
Part 21
Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease
Part 22
Session 11: SGLT2 inhibition in clinical practice
Part 23
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist
Part 24
Session 12: Managing obesity in the CRM setting
Part 25
Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy
Part 26
Meet the Expert: SGLT2, the statin of the 21st century
Part 27
Session 13: New trial update in nephrology
Part 28
Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options
Part 29
Session 14: Telemedicine in CRM
Part 30
Session 15: New drugs, new hopes and sometimes risks
Part 31
Meet the Expert: Management of worsening HF
Part 32
Session 16: Harmonising the gluco-and cardio-centric management of diabetes
Faculty Biographies

Ileana L Piña
Dr Ileana L Pina is Professor at the Department of Medicine (Cardiology) and Professor in the Department of Epidemiology and Population Health at Montefiore Einstein Center for Heart and Vascular Care, US.
Dr Piña has a particular research and clinical interest in rehabilitation of heart disease in patients with heart failure. She completed a NHLBI HF ACTION trial and is in the process of examining recovery after exercise which could be translated to an additional parameter that may better predict prognosis of outcomes. In addition, there was a R21 to NHLBI to examine Vitamin D levels as another predictor from the HF ACTION database.
Dr Ileana L Pina is an Editorial Board member of Cardiac Failure Review.